Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





KXL-II topography-guided cross-linking treatment for keratoconus

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cross-Linking

Session Date/Time: Sunday 06/09/2015 | 08:00-09:30

Paper Time: 09:18

Venue: Main Auditorium

First Author: : A.Behndig SWEDEN

Co Author(s): :    M. Schiller   M. Nordstrom   A. Fredriksson              

Abstract Details

Purpose:

To assess the refractive and safety results from KXL-II topography guided individualized corneal crosslinking (CXL) treatment in keratoconus, compared to conventlional CXL.

Setting:

Umeå University Hospital, Umeå, Sweden.

Methods:

In an ongoing study commenced March 2014, 25 + 25 eyes with keratoconus were randomized between conventlional CXL and KXL-II topography guided crosslinking treatment. The KXL-II uses an asymmetrical treatment zone, the size and location determined by the size and location of the cone as assessed with Oculus Pentacam HR. The delivered energy is determined by the maximum keratometry reading (Kmax), and ranges from 7.2 - 15 J/cm2. The overall aim with the treatment modification in KXL-II is to enhance the refractive improvement after CXL.

Results:

The spherical and cylindrical refraction showed improvement at 3 months after KXL-II (P<0.05), and the KXL-II-treated corneas showed an enhanced inferior corneal flattening and reduction in Kmax, compared to conventlional CXL (P<0.05). No differences in endothelial cell count were seen between the two treatments. Six-month data from this ongoing study will be presented.

Conclusions:

Topography guided individualized CXL shows refractive advantages over traditional CXL, with preserved corneal endothelial safety. In this first attempt to control and improve the refractive outcomes after CXL the effects are promising.

Financial Interest:

NONE

Back to previous